1 min read
Add as a preferred source on Google

CytomX to Receive $5 Million From Regeneron for Cancer Drug Milestone

The payment is tied to a preclinical milestone in the companies’ cancer drug development partnership.

An unmarked vial stands beside a pipette in a laboratory / TokenPost.ai
An unmarked vial stands beside a pipette in a laboratory / TokenPost.ai

CytomX Therapeutics, Inc. announced that it will receive $5 million from Regeneron after reaching a preclinical milestone in their cancer drug development partnership.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…